College Mental Health Project
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03345459|
Recruitment Status : Recruiting
First Posted : November 17, 2017
Last Update Posted : November 17, 2017
Depression is common and debilitating disorder which, among college students, is predictive of significant problems including higher rates of dropout and suicidal behaviors. Despite viable psychotherapeutic and pharmacological options, the majority of depressed college students, like others in the general population, do not pursue treatment. Further, barriers to care, both those involving practical issues and psychological factors, lead to high attrition rates from treatment, resulting in modest effect sizes in effectiveness trials. In reaction to these alarming figures and as a means of increasing accessibility and retention, effective internet-based treatment for depression have been developed and tested. Despite increased availability, response to internet-based treatment continues to vary substantially, yet, controlled trials show that a meaningful proportion of patients who receive internet-based therapy recover. Identifying individuals with a high likelihood of responding to internet-based treatment would enable clinicians to target this inexpensive treatment only to the patients with a high probability of responding; allowing more intensive treatments to be reserved for patients who would not respond to internet-based therapy. The development of a system to make this determination would represent a major advance and address an unmet need.
ICare is an online depression treatment that has been adapted for college students (e.g., language used, problems discussed, embedded images). Prior work by the developers of ICare have tested the internet-based treatment in diverse samples of depressed adults, and prior meta-analytic research has demonstrated that psychological treatments for depression in college students are as effective relative to trials carried out among depressed adults. The overarching goal of the study is to: (a) test whether depressed college students utilize ICare, (b) identify psychosocial and clinical characteristics that increase the likelihood of ICare utilization, and (c) identify multivariate characteristics that predict treatment response.
|Condition or disease||Intervention/treatment|
|Depression||Other: ICare Prevent (internet-based treatment for depression in college students)|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Participants are randomized to internet-based treatment (two-thirds of sample) or usual care (one-third of sample).|
|Masking:||None (Open Label)|
|Official Title:||College Mental Health Project|
|Anticipated Study Start Date :||November 20, 2017|
|Estimated Primary Completion Date :||October 30, 2019|
|Estimated Study Completion Date :||January 1, 2020|
Experimental: Internet-Based Treatment (ICare)
ICare Prevent is a 7-week internet-based treatment for depression that is primarily cognitive behavior therapy but targets broad-based mechanisms related to college students.
Other: ICare Prevent (internet-based treatment for depression in college students)
ICare Prevent (internet-based treatment for depression in college students): 7 weekly sessions and 1 booster session. Each session requires about 30-45 minutes to complete. All sessions are accessed online, and it is a guided treatment (i.e., each patient provided an eCoach).
No Intervention: Usual Care
Participants are notified that they have elevated distress, and additionally, they are provided a list of on-campus and community resources.
- Patient Health Questionnaire-9 (PHQ-9) administered at post-treatment [ Time Frame: Assess depressive symptoms over the prior 2 weeks. ]Self-report questionnaire assessing depression symptoms during the past 2 weeks. Scores on the PHQ-9 range from 0-27. Lower scores are indicative of less severe depressive symptoms.
- Generalized Anxiety Disorder - 7 item (GAD-7) administered at post-treatment [ Time Frame: Assess anxious symptoms over the prior 2 weeks. ]Self-report questionnaire assessing anxiety symptoms during the past 2 weeks. Scores on the GAD-7 range from 0-21. Lower scores are indicative of less severe anxious symptoms.
- EuroQol 5 (EQ-5D) administered at post-treatment [ Time Frame: Examines problems/symptoms over the prior 2 weeks. ]Comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each of the 5 items is rated on a scale from 1 to 3, and then summed to a total score. Lower scores are indicative of less severe problems.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03345459
|Contact: Randy P Auerbach, PhDfirstname.lastname@example.org|
|United States, Massachusetts|
|Belmont, Massachusetts, United States, 02478|
|Contact: Randy P Auerbach, PhD|